Latest data on SGLT2-inhibition: video interview with Christoph Wanner

ERA-EDTA

SGLT2 inhibitors have been regarded as a milestone in the treatment of type 2 diabetes. They have a beneficial influence on renal and cardiovascular endpoints. But can they slow CKD progression in non-diabetic patients, too? These and other questions are answered by the ERA-EDTA President, Christoph Wanner.

Watch the interview